| Neurodevelopmental outcome of children treated with antenatal thyrotropin-releasing hormone. | |
| | |
MedLine Citation:
|
PMID: 12165574 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate neurodevelopmental outcome until 2 years of age in children who participated in a multicenter antenatal thyrotropin-releasing hormone (TRH) trial to improve respiratory outcome and to lower mortality. METHODS: Neurodevelopmental outcome was studied in infants whose mothers were admitted to the Academic Medical Center and enrolled in the European Antenatal TRH trial. Mothers were treated for imminent preterm delivery (before 30 weeks) with corticosteroids plus either placebo (placebo-group) or TRH (TRH-group). TRH treatment consisted of 400 micro g every 8 hours up to 4 doses. Assessments included neurologic development at 12 months and psychomotor development at 12 and 24 months using the Bayley developmental scales. RESULTS: Sixty-two infants were included, 10 of whom died. Of the surviving infants, 24 received TRH and 28 received placebo. Ten infants were lost to follow-up. Each group consisted of 21 infants. Both groups were comparable regarding gestational age, birth weight, and time interval between trial medication and birth. However, in the TRH group, more respiratory problems, ventilator days, and chronic lung disease were found. Neurologic and motor outcome did not differ between the groups, but lower mental developmental index scores were found in the TRH group at both ages. CONCLUSIONS: Antenatal TRH treatment is associated with a delay in mental development. This study demonstrates the importance of long-term follow-up of perinatal intervention trials with possible consequences for neurodevelopmental outcome of the infant. |
| | |
Authors:
|
Judy M Briët; Loekie van Sonderen; Maarten Buimer; Kees Boer; Joke H Kok |
Related Documents
:
|
10524724 - Interpreting the inventory of interpersonal problems: subscales based on an interperson... 8772924 - The neonatal neurobiologic risk score: does it predict outcome in very premature infants? 7156984 - Reproductive, perinatal, and environmental variables as predictors of development of pr... 16472354 - Application of the revised infant temperament questionnaire for evaluating temperament ... 18254094 - Prophylactic systemic antibiotics to reduce morbidity and mortality in neonates with ce... 2726354 - Massive hepatomegaly, steatosis, and secondary plasma carnitine deficiency in an infant... |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article |
Journal Detail:
|
Title: Pediatrics Volume: 110 ISSN: 1098-4275 ISO Abbreviation: Pediatrics Publication Date: 2002 Aug |
Date Detail:
|
Created Date: 2002-08-07 Completed Date: 2002-09-16 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0376422 Medline TA: Pediatrics Country: United States |
Other Details:
|
Languages: eng Pagination: 249-53 Citation Subset: AIM; IM |
Affiliation:
|
Department of Neonatology, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. j.m.briet@amc.uva.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Child Development* Clinical Trials as Topic Delivery, Obstetric* Female Follow-Up Studies Humans Infant Infant, Newborn Infant, Premature Infant, Premature, Diseases / prevention & control* Neurologic Examination Obstetric Labor, Premature Pregnancy Psychomotor Performance* Thyrotropin-Releasing Hormone / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
24305-27-9/Thyrotropin-Releasing Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Factors that influence the willingness of private primary care pediatricians to accept more Medicaid...
Next Document: Survey of adverse drug reactions on a pediatric ward: a strategy for early and detailed detection.